Altimmune, Inc. (ALT) Company Overview

What does Altimmune do?

Altimmune, Inc. is a late clinical-stage biotechnology company listed on the Nasdaq Global Market. It does not operate like a diversified pharmaceutical manufacturer with multiple commercial products. Instead, almost the entire operating and valuation story is concentrated in pemvidutide, an investigational once-weekly peptide designed as a balanced 1:1 glucagon and GLP-1 receptor agonist. The company’s official pemvidutide overview explains the intended division of labor: glucagon activity is aimed at direct liver effects, while GLP-1 activity supports appetite suppression, weight loss, and metabolic improvement.

Which diseases define the pipeline?

The company reports as a single operating segment because it has one integrated research organization and no commercial product portfolio. That simplicity helps readers identify the key issue: Altimmune is not yet an earnings business; it is a financed development platform whose future economics depend on whether one molecule can generate credible clinical, regulatory, manufacturing, and commercial outcomes across several related liver diseases. The official pipeline page currently points to second-half 2026 initiation of PERFORMA, third-quarter 2026 RECLAIM topline data, and third-quarter 2026 completion of RESTORE enrollment.

How does Altimmune make money?

Altimmune has not generated material product-sales revenue. Its 2025 revenue was only $41,000, compared with $20,000 in 2024, so conventional revenue-growth analysis is not useful. The economic model is sequential: raise capital, fund clinical evidence, obtain regulatory approval, then commercialize directly or share economics with a partner. Until an approval or licensing transaction occurs, cash inflows mainly come from equity offerings, debt, interest on cash investments, and occasional research incentives.

What would the eventual revenue streams look like?

Which turning points shaped Altimmune’s current strategy?

Altimmune’s history is best understood as a concentration story. The company moved from a broader pipeline toward a single, liver-focused peptide platform, while clinical data progressively shifted pemvidutide from an obesity-adjacent asset into a MASH-centered late-stage program.

1. 2017
   The merger that created the current public-company structure provided a Nasdaq-listed vehicle and governance platform for subsequent pipeline development.
2. 2019
   Altimmune acquired Spitfire Pharma and pemvidutide. The agreement includes up to $80.0 million of sales milestones if specified worldwide net-sales thresholds are achieved after approval.
3. 2023–2024
   MOMENTUM and fatty-liver studies demonstrated weight loss, liver-fat reduction, and lean-mass preservation, giving the molecule a differentiated metabolic-and-liver thesis.
4. March 2024
   The HepTcell program was terminated, reducing diversification and increasing Altimmune’s dependence on pemvidutide.
5. June 2025
   IMPACT’s 24-week biopsy data showed statistically significant MASH resolution without worsening of fibrosis, although the fibrosis-improvement primary endpoint was not statistically significant.
6. December 2025
   Positive 48-week non-invasive fibrosis data and an end-of-Phase 2 FDA meeting established the basis for a registrational Phase 3 design.
7. January–June 2026
   Breakthrough Therapy Designation, new financing, a CEO transition to Jerry Durso, and a planned move to Morristown, New Jersey signaled a shift toward late-stage execution and commercial capability building.

What did the strategic narrowing accomplish?

The narrowing improved organizational focus: 57 employees at year-end 2025, including 16 with M.D. or Ph.D. degrees and 23 with other advanced degrees, can concentrate on one asset and related indications. It also created a clear mission—to become a leading biopharmaceutical company in serious liver diseases—supported by Phase 3 preparation, alternative formulations, and partnership evaluation in the 2025 Form 10-K.

The trade-off is concentration risk. A diversified pharmaceutical company can absorb one failed trial; Altimmune cannot. Every operational choice—from manufacturing contracts to hiring and financing—must therefore be judged by whether it improves the probability, timing, or economics of pemvidutide reaching patients.

What do pemvidutide’s clinical results show?

The 24-week IMPACT results established the strongest part of the clinical case: both pemvidutide doses achieved statistically significant MASH resolution without worsening of fibrosis versus placebo. However, fibrosis improvement without worsening of MASH was 32.6% and 35.7% for the 1.2 mg and 1.8 mg doses versus 27.9% for placebo, and the differences were not statistically significant. That distinction matters because a serious research brief must separate a met primary endpoint from an encouraging but unproven secondary dimension.

Why did the 48-week data strengthen the story?

At week 48, the 1.8 mg dose produced mean ELF and liver-stiffness reductions of 0.58 and 3.97, respectively, versus a 0.16 increase and 0.03 reduction for placebo. A combined response—at least a 0.5 ELF reduction and at least a 30% LSM reduction—occurred in 32.4% of the 1.8 mg group, 27.8% of the 1.2 mg group, and 3.2% of placebo patients. Treatment discontinuation due to adverse events was 1.2% for 1.8 mg, 0% for 1.2 mg, and 3.5% for placebo.

The FDA granted Breakthrough Therapy Designation in January 2026, and Altimmune plans to use biopsy endpoints plus the FDA-qualified AIM-MASH AI Assist tool in PERFORMA. The May 2026 IMPACT update adds reductions in waist circumference of 5.3 cm and blood pressure of 4.0/2.2 mmHg for systolic/diastolic measures. These data are meaningful, but Phase 3 must still confirm durable clinical benefit and an approvable benefit-risk profile.

What does Altimmune’s latest quarter show?

The quarter ended March 31, 2026 reflects a company preparing for larger trials rather than a company approaching profitability. R&D expense increased modestly to $16.2 million from $15.8 million in Q1 2025 as AUD, ALD, and PERFORMA startup costs replaced completed IMPACT work. G&A expense rose to $8.1 million from $6.0 million, primarily because of severance and professional fees. Interest income was $2.9 million, but the net loss widened to $22.6 million, or $0.18 per share, from $19.6 million, or $0.26 per share.

How much financing capacity did Altimmune add?

The balance sheet changed rapidly after quarter-end. Altimmune reported approximately $535 million of cash, cash equivalents, and short-term investments at April 30, 2026 after a $225.0 million gross public offering that produced approximately $211.2 million of net proceeds. This followed a January registered direct offering with approximately $70.3 million of net proceeds and $8.7 million of Q1 ATM proceeds. The Q1 2026 Form 10-Q is the clearest source for the quarter’s balance sheet and cash-flow details.

How financially strong is Altimmune?

Altimmune’s financial strength is best described as strong near-term liquidity paired with structurally negative operating economics. It has no meaningful product revenue, an accumulated deficit of $649.5 million at December 31, 2025, and recurring cash burn. Yet the 2026 financings materially extended the time available to execute PERFORMA and the alcohol-related programs.

What does the annual cost structure reveal?

Debt adds a second dimension. The funded principal was $35.0 million at March 31, 2026; the carrying amount was $34.5 million, and the weighted-average effective interest rate was 13.37%. The loan is secured by substantially all assets, restricts certain corporate actions, and matures in January 2029. With no principal due in 2026, debt is manageable near term, but it is more expensive and restrictive than cash raised through equity.

Who are Altimmune’s competitors, and what is its moat?

What could give pemvidutide a competitive advantage?

The proposed moat has four layers. First, the balanced 1:1 receptor profile is intended to combine direct liver activity with weight loss. Second, IMPACT showed low discontinuation without dose titration, a potentially valuable usability advantage. Third, Breakthrough Therapy and Fast Track designations can improve regulator interaction, though they do not guarantee approval. Fourth, the patent estate includes licensed and owned claims with expirations ranging from 2032–2035 and, for some pending indication, formulation, and dosing claims, potentially into 2039–2043.

This is not yet a durable commercial moat. It is a scientific and regulatory position that still must survive Phase 3, manufacturing validation, payer scrutiny, and competitors with far greater resources. The best interpretation is “differentiated asset, unproven franchise.”

Who owns Altimmune stock, and how is it governed?

Altimmune has one common share class with one vote per share and no preferred stock outstanding at March 31, 2026. That means control is not concentrated through a founder super-voting structure. Influence comes mainly from institutions, the board, and management’s ability to finance and execute the development plan.

What changed in leadership?

The 2026 proxy statement shows that directors and officers collectively controlled only 1.6% on the proxy measurement date. Investors therefore depend heavily on board quality, capital-market discipline, and compensation design rather than a founder-owner’s concentrated economic commitment. The rapid expansion from 110.9 million shares at December 31, 2025 to 194.5 million shares outstanding at May 8, 2026 also means governance must be read alongside dilution: the company gained substantial cash, but each pre-financing share represents a smaller fraction of the enterprise.

What opportunities and risks could change Altimmune’s outlook?

Which risks are most material?

The opportunity case is equally specific. A successful MASH Phase 3 trial could position pemvidutide as a therapy addressing both liver pathology and metabolic drivers. Positive AUD data would broaden the narrative beyond MASH and create a potentially differentiated approach to alcohol-related disease. Meanwhile, the company’s planned headquarters move to Morristown, New Jersey is intended to improve access to biopharmaceutical talent as the organization matures; the June 2026 Form 8-K frames the relocation as part of late-stage growth.

Why does Altimmune matter for valuation?

A standard DCF built from current revenue and margins would be meaningless because current revenue is effectively zero. Altimmune requires a risk-adjusted pipeline valuation. The analyst estimates the probability, timing, and commercial economics of each indication, subtracts future development and commercialization costs, discounts the resulting cash flows, then adjusts for cash, debt, milestone obligations, and fully diluted shares.

Which KPIs should a model update each quarter?

• Clinical schedule: PERFORMA startup, enrollment rate, protocol changes, and major data dates.
• Safety and persistence: adverse-event discontinuations, dose interruptions, and long-term tolerability.
• Liquidity: cash plus investments, quarterly operating cash burn, debt balance, and unused financing capacity.
• Dilution: basic shares, warrants, options, RSUs, and any ATM issuance.
• Portfolio optionality: RECLAIM and RESTORE outcomes, new formulations, and partnership terms.

The most important sensitivity is not the discount rate; it is the probability-adjusted commercial scenario. A small change in assumed Phase 3 success, label breadth, or peak penetration can move intrinsic value far more than a modest change in terminal growth. That is why the official Breakthrough Therapy announcement matters: it improves regulatory interaction and validates preliminary evidence, but it should increase—not replace—the analyst’s attention to Phase 3 design and execution.

What is the key takeaway from Altimmune analysis?

Altimmune is important because it is attempting to turn a single balanced glucagon/GLP-1 molecule into a liver-disease franchise. The strongest evidence is the combination of statistically significant MASH resolution at 24 weeks, continued improvement in non-invasive fibrosis markers at 48 weeks, favorable discontinuation rates, and broad metabolic effects. The company also entered mid-2026 with substantially more liquidity, FDA alignment on Phase 3 parameters, Breakthrough Therapy Designation, and a management team being reshaped for late-stage development.

What could support or weaken the story?

For students, Altimmune is a useful case study in focused strategy, resource dependence, clinical-regulatory sequencing, and the difference between accounting performance and asset value. For investors and researchers, the central tension is equally clear: the company has enough capital to pursue a more ambitious development plan, but that capital was purchased through a much larger share base, and it still finances an unapproved single asset.